| Filed On | Filing |
|---|---|
| 28 Oct 2026 |
8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities +1 more
LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Q2 2026 total revenue of $5.5 million from VIZZ product sales and global license agreements |
| 02 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 30, 2026, Zach Scheiner notified LENZ Therapeutics, Inc. a Delaware corporation (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”) and from all committees of the Board on which he ser... |
| 12 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
LENZ Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders on June 12, 2026 (the “Annual Meeting”). Of the 31,354,394 shares of the Company’s common stock outstanding as of the record date of April 14, 2026, 24,... |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition
Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ® product sales |
| 24 Mar 2026 |
8-K: Results of Operations and Financial Condition
Launched VIZZ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch |
| 07 Jan 2026 |
8-K: Results of Operations and Financial Condition
Launched VIZZTM (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025 |
| 12 Dec 2025 |
8-K: Other Events
LENZ Therapeutics, Inc. (“the Company”) is aware of a recent adverse event report submitted to the U.S. Food and Drug Administration’s (“FDA”) Adverse Event Reporting System (“FAERS”) database describing a retinal tear in a patient using... |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
VIZZTM (aceclidine ophthalmic solution) 1.44% received FDA approval for the treatment of presbyopia |
| 08 Oct 2025 |
8-K: Other Events
On October 7, 2025, the Company sold 1,748,634 shares of common stock at a purchase price of $45.75 per share for gross proceeds of approximately $80,000,000 in a block trade to a single investor under the Company's "at the market" Sales... |
| 30 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
VIZZ sample distribution initiated nationwide to Eye Care Professionals |
| 31 Jul 2025 |
8-K: Other Events
VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States |
| 30 Jul 2025 |
8-K: Results of Operations and Financial Condition
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 |
| 10 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
LENZ Therapeutics, Inc. (the “Company”) held its 2025 annual meeting of stockholders on June 10, 2025 (the “Annual Meeting”). Of the 27,544,520 shares of the Company’s common stock outstanding as of the record date of April 14, 2025, 17,... |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 |
| 15 Apr 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
LENZ Therapeutics, Inc. (the “Company”) is filing this Current Report on Form 8-K in connection with the previously announced Commercial Day to be held on April 15, 2025, to announce that the Company’s cash, cash equivalents and marketab... |
| 04 Apr 2025 |
8-K: Entry into a Material Definitive Agreement
LENZ Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: |
| 19 Mar 2025 |
8-K: Results of Operations and Financial Condition
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 |
| 06 Nov 2024 |
8-K: Results of Operations and Financial Condition
New Drug Application (NDA) for LNZ100 for treatment of presbyopia accepted for review by the U.S. Food and Drug Administration (FDA); PDUFA target action date of August 8, 2025 |
| 28 Oct 2024 |
8-K: Other Events
Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment,and maintaining their optimal distance visual acuity (i.e., not losing 5 or more letters). The dif... |
Loading...